Literature DB >> 17997280

Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients.

Anvita Kale1, Sadhana Joshi, Nilesh Naphade, Swati Sapkale, M S V K Raju, Anilkumar Pillai, Henry Nasrallah, Sahebarao P Mahadik.   

Abstract

Variable levels of essential polyunsaturated fatty acids (EPUFAs) reported in schizophrenia are likely due to differences in age, sex, ethnicity, diet, life style and treatments. The present study examined the EPUFAs levels in plasma, RBC and CSF in never-medicated first-episode psychotic patients and normal controls matched for ethnicity, diet and life style. The plasma EPUFAs levels were similar in both groups. Among the EPUFAs enriched in the brain, predominantly docosahexaenoic acid (DHA) levels were lower in RBC (p=<0.01) whereas higher in CSF (p=<0.01) in male>female patients. This altered DHA metabolism may provide clues for neuropathology and treatment of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997280     DOI: 10.1016/j.schres.2007.09.036

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

Review 1.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

2.  Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis.

Authors:  Robert K McNamara; Jessica A Able; Ronald Jandacek; Therese Rider; Patrick Tso
Journal:  Schizophr Res       Date:  2008-11-07       Impact factor: 4.939

3.  Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species.

Authors:  Kei Hamazaki; Kwang H Choi; Hee-Yong Kim
Journal:  J Psychiatr Res       Date:  2010-01-06       Impact factor: 4.791

4.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 5.  Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan.

Authors:  Natalie Sinn; Catherine Milte; Peter R C Howe
Journal:  Nutrients       Date:  2010-02-09       Impact factor: 5.717

6.  Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies.

Authors:  Chie Shimamoto; Tetsuo Ohnishi; Motoko Maekawa; Akiko Watanabe; Hisako Ohba; Ryoichi Arai; Yoshimi Iwayama; Yasuko Hisano; Tomoko Toyota; Manabu Toyoshima; Katsuaki Suzuki; Yukihiko Shirayama; Kazuhiko Nakamura; Norio Mori; Yuji Owada; Tetsuyuki Kobayashi; Takeo Yoshikawa
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

Review 7.  Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.

Authors:  Mei-Chi Hsu; Yung-Sheng Huang; Wen-Chen Ouyang
Journal:  Lipids Health Dis       Date:  2020-07-03       Impact factor: 3.876

8.  Adult medication-free schizophrenic patients exhibit long-chain omega-3 Fatty Acid deficiency: implications for cardiovascular disease risk.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Yogesh Dwivedi; Ghanshyam N Pandey
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-02-27

9.  Relationship between central and peripheral fatty acids in humans.

Authors:  Jade Guest; Manohar Garg; Ayse Bilgin; Ross Grant
Journal:  Lipids Health Dis       Date:  2013-05-28       Impact factor: 3.876

10.  Lipid Pathology of the Corpus Callosum in Schizophrenia and the Potential Role of Abnormal Gene Regulatory Networks with Reduced Microglial Marker Expression.

Authors:  Chie Shimamoto-Mitsuyama; Akihiro Nakaya; Kayoko Esaki; Shabeesh Balan; Yoshimi Iwayama; Tetsuo Ohnishi; Motoko Maekawa; Tomoko Toyota; Brian Dean; Takeo Yoshikawa
Journal:  Cereb Cortex       Date:  2021-01-01       Impact factor: 5.357

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.